| Market Capitalization (Millions $) |
30 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-58 |
| Cash Flow (TTM) (Millions $) |
-11 |
| Capital Exp. (TTM) (Millions $) |
0 |
Rallybio Corporation
Rallybio Corporation is a US-based biopharmaceutical company that is focused on the development of novel treatments for rare and serious diseases. Founded in 2018, the company has quickly become one of the leading players in the biotech industry, thanks to its innovative drug discovery platform and strong team of scientists, researchers, and business professionals.
The mission of Rallybio Corporation is to discover and develop life-changing therapies that can address unmet medical needs in patients with rare diseases. The company is dedicated to advancing the science of drug development and pushing the boundaries of what is possible in the field of biotechnology.
One of the key strengths of Rallybio Corporation is its deep expertise in the biology of rare diseases. The company's team of experts includes some of the most renowned scientists and researchers in the field, who have a wealth of experience in the discovery and development of new treatments for rare and orphan diseases.
Rallybio Corporation is currently focusing on the development of a pipeline of innovative drug candidates that have the potential to transform the lives of patients with rare and serious illnesses. The company's lead program is a monoclonal antibody therapy designed to treat patients with severe hemophilia A.
In addition to its lead program, Rallybio Corporation has a number of other drug candidates in the pipeline, including treatments for rare genetic disorders such as lysosomal storage diseases, immune-mediated diseases, and other serious conditions.
One of the key factors that sets Rallybio Corporation apart from its competitors is its strategic approach to drug development. The company is focused on developing targeted therapies that address the specific molecular mechanisms that underlie rare diseases, which enables them to deliver highly effective and precise treatments that have minimal side effects.
Overall, Rallybio Corporation is an exciting and dynamic biotech company that is making significant strides in the discovery and development of innovative drug therapies for rare and serious diseases. With its strong team of experts and cutting-edge technology platform, the company is well-positioned to become a major player in the biotech industry over the coming years.
Company Address: 234 Church Street New Haven 6510 CT
Company Phone Number: 859-3820 Stock Exchange / Ticker: NASDAQ RLYB
|
14.95% 